Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 1/2 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 38Thoracic 28Genitourinary 28Gastrointestinal 22CNS 13Sarcoma 10Head & Neck 9Lymphoid 7Other hematologic neoplasm 6Gynecologic 6Endocrine 6Breast 6Other solid neoplasm 5Tumor-Agnostic 4Plasma cell 4Myeloid 4NET 2

Conditions

Neoplasms 2Neoplasm Metastasis 2

Interventions

pembrolizumab 24Specimen Handling 22Biopsy 22Magnetic Resonance Spectroscopy 19Paclitaxel 11Standard of Care 10Bevacizumab 10atezolizumab 9Carboplatin 9Nivolumab 8Cisplatin 8Blood Specimen Collection 8Surveys and Questionnaires 7Capecitabine 7Radiosurgery 6Pemetrexed 6Gemcitabine 6Cyclophosphamide 6durvalumab 5Taxes 5Irinotecan 5trastuzumab deruxtecan 4olaparib 4niraparib 4cabozantinib 4X-Rays 4Radiotherapy 4Oxaliplatin 4Leucovorin 4Ipilimumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Ipilimumab × Tumor-Agnostic × 90 days × Clear all
NCT03899155 2026-05-27

Pan Tumor Rollover Study

Bristol-Myers Squibb

Phase 2 Recruiting
1,500 enrolled
Tumor-Agnostic

Neoplasms

NCT04317105 2026-05-13

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
54 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05219435 2026-04-24

VEXILLUM

Spanish Oncology Genito-Urinary Group

Phase 2 Completed
25 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT06031233 2026-03-30

MINUTE

Isala

Phase 4 Recruiting
776 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡